US Bankruptcy Chapter 11 Insolvency SEC Filings — February 11, 2026

Filed 8-K disclosing bankruptcy/receivership under Item 1.03 on 2026-02-11, no financial impacts or assets/debts detailed

Absence of YoY/QoQ period comparisons in filing signals deteriorating financial health with no growth trends visible

No forward-looking statements, guidance, or restructuring plans provided, eliminating any reorganization upside

Lack of insider trading activity data (buys/sells/pledges) amid crisis indicates zero management conviction

No capital allocation details (dividends, buybacks, splits) mentioned, suggesting halted shareholder returns

Bearish sentiment with critical risk level (10/10 materiality) and no positive operational metrics like volumes/capacity

Risk factors highlight severe uncertainty vs. peers (sole filing), potential Chapter 7 liquidation over Chapter 11

No M&A/transaction details or valuations, ruling out strategic sale as near-term catalyst

Financial ratios (e.g., Debt-to-Equity, ROE) not disclosed amid insolvency, implying unsustainable leverage

No scheduled events (earnings calls, AGMs) listed, delaying visibility into proceedings

Outperforms no peers in stream (sole filer), underperforms market with bankruptcy as outlier negative

Mixed sentiment absent; purely bearish with no counterbalancing positives in enriched data

Disclosure under Item 1.03 introduces operational shutdown risks, no proceedings type specified

Potential stock delisting post-filing, erasing equity value for shareholders

Unquantified debts/assets signal priority creditor recovery over equity

Lack of Chapter 11 reorganization details raises Chapter 7 liquidation probability

No period-over-period trends (YoY/QoQ revenue/margins) provided in critical filing

Absence of forward-looking forecasts/targets eliminates recovery timeline visibility

Zero insider activity (transactions/holdings) data amid crisis flags management exodus risk

No dividend/buyback updates, implying frozen capital allocation in insolvency

Undisclosed ratios/ops metrics (ROE, costs) suggest pre-filing decline trends

Lack of scheduled earnings/AGMs delays court docket monitoring

Bankruptcy filing enables put options or direct shorts ahead of delisting

Monitor for creditor claims; potential entry into senior debt at deep discount

If Chapter 7 confirmed, asset sales could yield vulture fund alpha vs. equity wipeout

Relative short ZYNEX vs. healthy medtech peers (e.g., no insolvency filings)

Post-filing spike in options volume for straddles on proceedings uncertainty

Use as sector hedge in healthcare amid 2026 insolvency theme emergence

Watch for restructuring plan filing; contrarian long if Chapter 11 terms favorable

Any post-filing insider buys could signal turnaround, absent now

1/1 filings in period disclose insolvency event, signaling early 2026 stress in medtech

No enriched data on trends/guidance across stream heightens uncertainty for insolvency tracking

Zero dividend/buyback details in sole filing indicates sector-wide halt in shareholder allocation

10/10 risk in single event vs. typical filings flags accelerating corporate failures

Lack of Chapter 11 plans or timelines across filings suggests liquidation bias

No transactions/pledges reported, pattern of management disengagement in distress

Monitor docket for Chapter 11 vs. 7 classification, debtor filings imminent post-2026-02-11

Track Form 4s for buys/sells/pledges by executives amid crisis, none currently

Watch for 8-K/10-Q updates on plans, assets/debts disclosure expected Q1 2026

SEC/Nasdaq alerts on trading halt/delisting post-bankruptcy event

Bankruptcy court filings for claims, timelines within 30-60 days of 2026-02-11

Future filings for YoY/QoQ revenue decline, margin compression details

Any forward-looking statements in proceedings could shift sentiment

Comparative insolvencies in medtech, building on ZYNEX as lead indicator